Melbourne, Australia, 03 June 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
This year’s Biotechnology Innovation Organisation (BIO) International Convention will be attended by OccuRx and its management team including Chief Executive Officer, Professor Darren Kelly.
The BIO convention is set to take place in Philadelphia, Pennsylvania between 3rd – 6th June 2019 and represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organisations across the United States and in more than 30 other nations.
The OccuRx team will highlight their scientific advancements in anti-inflammatory and anti-fibrotic therapies, including their clinical development progress and plans with its novel therapeutic platform. The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
This conference will allow the OccuRx team to network with BIO members who are focused on the research and development of innovative healthcare and biotechnology products.
BIO includes four days of detailed programming and exhibitions, including 17,300 attendees, 126 educational sessions, more than 800 speakers, over 250 company presentations, 1,800 exhibitors, unlimited networking opportunities and unparalleled partnering.